US FDA's Shutdown Offers One Possible Winner
Executive Summary
For most sponsors, shutdown's impact won’t be too dramatic – but for two peanut allergy companies, the stoppage had very different implications.
You may also be interested in...
Shutdown Deal Avoids Further US FDA Service Cuts, But Damage May Linger
Employees are no doubt are excited to resume work and may have a dozen or more major NDAs pending, but agency morale may not recover quickly.
Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers
FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.